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Murine double minute (MDM2) is an E3 ligase that promotes ubiquitination and degradation of
tumor suppressor protein 53 (p53). MDM2-mediated regulation of p53 has been investigated as a
classical tumorigenesis pathway. Here, we describe TRIAD1 as a novel modulator of the p53-
MDM2 axis that induces p53 activation by inhibiting its regulation by MDM2. Ablation of TRIAD1
attenuates p53 levels activity upon DNA damage, whereas ectopic expression of TRIAD1 promotes
p53 stability by inhibiting MDM2-mediated ubiquitination/degradation. Moreover, TRIAD1 binds
to the C-terminus of p53 to promote its dissociation from MDM2. These results implicate TRIAD1
as a novel regulatory factor of p53-MDM2.
Structured summary of protein interactions:
p53 physically interacts withMdm2 and Triad1 by anti tag coimmunoprecipitation (View Interaction: 1,
2, 3)
Mdm2 physically interacts with Triad1 by anti tag coimmunoprecipitation (View interaction)
p53 physically interacts with Mdm2 by anti tag coimmunoprecipitation (View interaction)
Triad1 binds to p53 by pull down (View interaction)
Mdm2 physically interacts with p53 by anti tag coimmunoprecipitation (View interaction)
p53 physically interacts with Triad1 by anti tag coimmunoprecipitation (View interaction)
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction synthetic antagonist of MDM2 that stabilizes p53 by inhibitingThe ubiquitination-mediated proteasomal degradation pathway
is a predominant regulatory mechanism that promotes rapid p53
degradation. Although acetylation and phosphorylation are key
processes associated with p53 control during cellular stress, p53
ubiquitination is directly related to its stability because it disrupts
interactions with p53-speciﬁc ubiquitin E3 ligases [1].
Several studies have investigated the antagonistic action of
MDM2 in the MDM2-p53 axis by using chemical antagonists and
other molecules involved in the signaling pathways. Nutlin3 is achemical Societies. Published by E
T, glutathione S-transferase;
sor protein 53; RING, really
DRIL 1
g Research Centre and Korea
niversity, 1 Hwayang-dong,
+82 2 3437 4055.the p53-MDM2 interaction [2]. ADP ribosylation factor (ARF), a
tumor suppressor that is deleted in several cancers, activates p53
by inhibiting its interaction with MDM2 [3,4], and ribosomal
proteins such as L11, L23, and L5 inhibit MDM2 activity and
disrupt p53 regulation [5]. Ubiquitination can also regulate the
p53-MDM2 axis. The herpes virus-associated ubiquitin-speciﬁc
protease is capable of deubiquitinating both p53 and MDM2 and
regulates MDM2 stability [6]. Moreover, HDM2 is ubiquitinated
by P300/CBP-associated factor (PCAF) and undergoes proteolysis
via a proteasome-dependent mechanism that results in p53 activa-
tion [7]. Thus, mechanisms that govern the interaction between
p53 and MDM2 are important for p53 activity regulation.
We previously reported two RING ﬁngers and DRIL 1 (TRIAD1)-
mediated apoptosis in various cell lines. In particular, we showed
that p53 is indispensible for TRIAD1-mediated apoptosis in several
cancer cell lines and that TRIAD1 induces p53 transactivation [8].
However, a deﬁnitive mechanism for TRIAD1-mediated p53lsevier B.V. All rights reserved.
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onstrate that TRIAD1 induces p53 activation by promoting the dis-
sociation of p53 from MDM2. These results indicate a novel
TRIAD1-p53-MDM2 regulatory model.2. Materials and methods
2.1. Plasmids
Human TRIAD1 cDNA and fragments (1–246 amino acids [a.a.]
and 247–493 a.a.) were subcloned into pcDNA3.1-Myc/His (Invit-
rogen, Carlsbad, CA), pEGFP-C1 (Clontech, Mountain View, CA),
and pGEX6p (Promega, Madison, WI) vectors. Human MDM2 cDNA
was subcloned into a pCMV-Tag2-FLAG vector (Stratagene, La Jolla,
CA). Human p53 cDNA and fragments (1–61 a.a., 1–92 a.a., 1–292
a.a., 1–359 a.a., and 1–393 a.a.) were cloned into pcDNA3.1-HA
(Invitrogen) and pGEX6p (Promega) vectors. RING domain-mutant
MDM2 (MDM2-C438A) was generated using a QuikChange site-
directed mutagenesis kit (Stratagene) according to the manufac-
turer’s instructions. The p53 C135Y mutant was kindly provided
by Dr. Carl G. Maki (University of Chicago, Chicago, IL). The
HA-ubiquitin (HA-Ub) plasmid pMT123 was kindly provided by
Dr. Dirk Bohmann (University of Rochester, Rochester, NY).
2.2. Antibodies and reagents
Antibodies against p53 (DO-1 and FL-393), HA (Y-11 and F-7),
MDM2 (SMP14 and D-12), TRIAD1 (F-23), and ubiquitin (P4D1),
as well as normal mouse and rabbit IgGs and protein A/G
PLUS-agarose beads were from Santa Cruz Biotechnology (Santa
Cruz, CA). Anti-actin and anti-FLAG antibodies were purchased
from Sigma–Aldrich (St. Louis, MO). Anti-Myc-tag and anti-GFP
antibodies were purchased from Cell Signaling Technology
(Danvers, MA).
2.3. Cell culture and transfection
Wild-type mouse embryonic ﬁbroblasts (MEFs), p53/ MEF,
and p53/mdm2/ MEF cells were maintained in Dulbecco’s min-
imum essential media (Invitrogen) supplemented with 10% fetal
bovine serum (FBS) and 1% penicillin/streptomycin (Invitrogen).
U2OS cells were maintained in RPMI 1640 media with 10% FBS
and 1% penicillin/streptomycin. Transient transfections were car-
ried out using HilyMax (Dojindo Laboratories, Kumanoto, Japan)
according to the manufacturer’s instructions.
2.4. TRIAD1 stable knockdown
For the shRNA-mediated knockdown of TRIAD1, pairs of syn-
thetic DNA oligos (forward, 50-GGACCGGTGGGAGGACTATTACGT
GGGAGTACTCGAGTAC-30; reverse, 50-CCGGAATTCCCAAAAAGAG-
GACTATTACGTGGGAGTACTCGA-GTAC-30) were annealed in 50-ll
volumes with 20 lM of each oligo in PCR buffer, 250 lM dNTP,
and 1.25 units of TaKaRa Ex-Taq DNA polymerase (TaKaRa Bio
Inc., Ohtsu, Japan). The samples were incubated at 95 C for
4 min, 30 C for 10 min, and 72 C for 60 min. The shRNA duplex
oligos were cloned into pLKO.1 puro (Addgene, Cambridge, MA).
A TRIAD1 stable knockdown cell line was established using lentiv-
iral gene-transfer. Brieﬂy, 293T cells were cotransfected with
TRIAD1 shRNA lentiviral transfer, pCMV-delta8.9, and pVpack-
VSV-G plasmids (Stratagene). At 48 h after transfection, viral parti-
cle-containing medium was collected and used to infect U2OS
cells, which were incubated with 1 lg/ml puromycin to establish
TRIAD1-knockdown cells.2.5. Ubiquitination assays
In vivo ubiquitination assay was performed as previously de-
scribed [27]. Brieﬂy, transfected and MG132-treated cells were
washed with PBS and then lysed in 200 ll of SDS-containing lysis
buffer (50 mM Tris–HCl, pH 7.5, 70 mM b-mercaptoethanol, 0.5%
SDS) by vortexing and boiling for 10 min at 95 C. The lysates were
diluted with 800 ll of NP-40 lysis buffer (50 mM Tris–HCl, pH 7.5;
150 mM NaCl; 1% NP-40; 1 mM DTT; 1 mM EDTA; 10 lg lysozyme;
and 0.5 mM PMSF). The lysates were immunoprecipitated with
indicated antibody and protein agarose A/G PLUS-Agarose beads.
The beads were washed ﬁve times in NP-40 buffer and then boiled
in SDS–PAGE sample buffer. The bound ubiquitinated p53 proteins
were analyzed by immunoblotting using an indicated antibody.
2.6. In vitro binding assay
GST and GST-TRIAD1 proteins were expressed in Escherichia coli
BL21 at 25 C with 0.1 mM IPTG for overnight. The cells were col-
lected and resuspended in NP-40 lysis buffer. The recombinant
proteins were isolated and eluted using glutathione-Sepharose
4B beads (GE Healthcare, Uppsala, Sweden) according to the man-
ufacturer’s instructions. 35S-labeled p53 protein obtained by
in vitro transcription/translation was incubated with 20 ll 50%
glutathione-Sepharose 4B-bound GST or GST-TRIAD1 recombinant
protein for 3 h at 37 C in binding buffer (30 mM Tris–HCl, pH 8.0;
0.1 mM EDTA; 0.1 mM NaCl; 1 mM DTT; 1% NP-40; and 0.5 mM
PMSF), washed ﬁve times, and boiled in SDS-sample buffer. The
bound proteins were separated by SDS–PAGE and visualized by
autoradiography.
2.7. Immunoprecipitation and immunoblotting
For the immunoprecipitation assay, cell lysates in CHAPS buffer
(0.5% CHAPS; 10 mM Tris–HCl, pH 7.5; 1 mM MgCl2; 1 mM EGTA;
5 mM b-mercaptoethanol; 10% glycerol) were incubated overnight
with the indicated antibodies at 4 C. After adding protein A/G
PLUS-agarose beads (Santa Cruz Biotechnology), the cell lysates
were further incubated for 2 h, and washed extensively. The
immunoblotting assay was carried out as previously described.
Western blot band intensities were compared with the Java-based
image-processing program ImageJ (National Institutes of Health,
Bethesda, MD), according to the software developers’ protocol.
Brieﬂy, the developed X-ray ﬁlms were scanned on a ﬂatbed scan-
ner. The blot images were opened with ImageJ, each lane in the
blot was selected, and the band densities were measured. All p53
band intensities were normalized to the respective b-actin inten-
sity to quantify relative p53 expression. These values are presented
as a ratio and graphically represented.
2.8. Cell viability assays
Cell proliferation ratios were measured using an MTS assay kit
(Promega) according to the manufacturer’s instructions. Brieﬂy,
cells (1  103) were transfected with GFP, GFP-TRIAD1, HA-p53,
or FLAG-MDM2 expression plasmids and further cultured for
48 h. MTS/PMS solution was added to each well and incubated at
37 C for 2 h. Absorbance was measured at 490 nm using a micro-
plate reader. The cell proliferation ratio relative to that of control
cells was graphically represented.
2.9. Colony formation assays
Cells (4  104) were transfected with the GFP, GFP-TRIAD1, HA-
p53, or FLAG-MDM2 plasmids, incubated for 24 h, and selected
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stained with 0.1% crystal violet.
2.10. Statistical analysis
Statistical analysis was performed using two-tailed Student’s
t-tests. Values of P < 0.05 were considered signiﬁcant.
3. Results
3.1. TRIAD1 is involved in p53 activation following DNA damage
We previously demonstrated that TRIAD1 induces apoptosis by
p53 activation [8]. These results led to us to evaluate the speciﬁc
role of TRIAD1 by measuring p53 accumulation in camptothecin
(CPT)-exposed TRIAD1-knockdown U2OS cells. Stable TRIAD1-
knockdown U2OS cells were generated by using lentiviral shTRI-
AD1 (see Section 2). Knockdown was conﬁrmed by quantitative
RT-PCR (data not shown). We observed that p53 protein levels in-
creased following CPT treatment in U2OS control cells in a dose-
dependent manner (left, Fig. 1A). However, these increased levels
of p53 protein were largely attenuated in TRIAD1-knockdown
U2OS cells (right, Fig. 1A). Furthermore, the expression levels of
targets downstream of p53, such as p21 and PUMA, were attenu-
ated by TRIAD1 knockdown following CPT exposure (Fig. 1B). We
also observed that ectopic TRIAD1 expression substantially in-
creased p53 protein levels in U2OS cells (Fig. 1C). Collectively,
these results indicate that TRIAD1 is required for p53 activation
following DNA damage.Fig. 1. Ablation of TRIAD1 reduces p53 activation following DNA damage. (A) Ablatio
Immunoblots were performed using indicated antibodies after treatment of control and
expression levels of genes downstream of p53 following CPT treatment. Immunoblots we
knockdown cells containing shTRIAD1. (C) Overexpression of TRIAD1 induced p53 accum
standard deviations of the relative p53 intensities obtained from triplicate experiments3.2. TRIAD1 regulates p53 stability
p53 activation is closely dependent on its stability, which is
tightly regulated by various mechanisms [9,10]. Based on the
observation that TRIAD1 is required for p53 activation (Fig. 1),
we measured p53 stability following the ectopic expression of
TRIAD1 in U2OS cells to determine whether it is regulated by
TRIAD1. Indeed, p53 stability was increased in TRIAD1-transfected
U2OS cells (Fig. 2A). Conversely, kinetic analyses of p53 stability
following cycloheximide (CHX) treatment in TRIAD1-knockdown
U2OS cells revealed that p53 half-life was shorter in TRIAD1-
knockdown cells than in control cells (Fig. 2B). Together, these re-
sults indicate that p53 stabilization is inﬂuenced by TRIAD1
expression.
3.3. TRIAD1 antagonizes MDM2-mediated p53 degradation
Given that p53 stability is mainly regulated by the RING do-
main-containing E3 ubiquitin ligase MDM2 [11,12], we examined
whether TRIAD1 might functionally antagonize MDM2 activity.
The exogenous expression levels of both wild-type and transcrip-
tionally mutant p53 (p53 C135Y) were increased following TRIAD1
overexpression, indicating that TRIAD1-induced p53 accumulation
was independent of p53 activity (Fig. 3A). Next, we examined
whether TRIAD1-mediated p53 stabilization might antagonize
the activities of MDM2 E3 ligase or other E3 ligases that target
p53. Interestingly, cotransfection of HA-tagged p53 and Myc-
tagged TRIAD1 plasmids into p53/ mdm2/ MEF cells did not
induce p53 accumulation compared with single HA-tagged p53n of TRIAD1 attenuates accumulation of p53 after camptothecin (CPT) treatment.
TRIAD1 knockdown U2OS cells with 5 lM CPT. (B) Ablation of TRIAD1 attenuates
re performed using indicated antibodies after CPT treatment of control and TRIAD1
ulation in a concentration-dependent manner. The graph represents the means and
.
Fig. 2. p53 half-life is regulated by TRIAD1. (A) Ectopic expression of TRIAD1 increases p53 stability. At 24 h after transfection with pcDNA3 control or Myc-tagged TRIAD1
plasmid, U2OS cells were treated with CHX (150 lg/ml) as indicated. Endogenous levels of p53 were measured by immunoblotting, and residual cellular levels of p53 were
quantitated by densitometry. The values are an average of two independent experiments. (B) Ablation of TRIAD1 reduces the stability of p53. Stable TRIAD1-knockdown U2OS
cells were incubated with cycloheximide (CHX, 150 lg/ml) for the indicated times. The values are an average of two independent experiments.
Fig. 3. TRIAD1 inhibits MDM2-mediated p53 degradation. (A) TRIAD1-induced p53 accumulation is independent of p53 activity. p53/ MEF cells were cotransfected with
plasmids as indicated. At 48 h after transfection, cell extracts were subjected to immunoblotting with the indicated antibodies. (B) TRIAD1 blocks MDM2-mediated p53
degradation. p53/mdm2/ MEF cells were cotransfected with the indicated plasmids. At 48 h after transfection, cell extracts were subjected to immunoblotting with the
indicated antibodies. (C) TRIAD1 inhibits MDM2-mediated p53 ubiquitination. After transfection, p53 ubiquitination was analyzed by immunoblotting (with an anti-HA
antibody, right panel) using immunoprecipitates obtained with the anti-FLAG antibody.
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completely inhibited by TRIAD1 expression (Fig. 3B). Consistent
with these results, TRIAD1 completely eliminated MDM2-medi-
ated p53 ubiquitination (Fig. 3C). Collectively, these data indicate
that TRIAD1 promotes p53 stability and activity, most likely by
antagonizing MDM2 activity.3.4. TRIAD1 inhibits the interaction between p53 and MDM2
A basic requirement for p53 degradation is the direct interac-
tion between p53 and MDM2. Because TRIAD1 interacts with p53
in vitro (Fig. S1), we evaluated the interaction between p53 and
MDM2 following TRIAD1 transfection. As shown in Fig. 4A and B,
Fig. 4. The N-terminal region of TRIAD1 inhibits the interaction between p53 and MDM2. (A and B) The interaction between p53 and MDM2 is inhibited by TRIAD1. p53/
mdm2/ MEF cells were transfected with the indicated plasmids. At 24 h after transfection, cells were treated with 1 lM MG132 for 12 h. Immunoprecipitates were
immunoblotted with anti-HA or anti-FLAG antibody. Whole cell lysates (WCLs) were analyzed by immunoblotting using the indicated antibodies as controls (lower panel). (C)
The TRIAD1 fragment (1–246 amino acids) is indispensible for binding p53 to inhibit the interaction between p53 and MDM2. TRIAD1 fragment constructs were generated as
represented in the left panel. p53/mdm2/ MEF cells were transfected with the indicated plasmids. Anti-HA immunoprecipitates were immunoblotted with anti-FLAG and
anti-GFP antibodies (upper panel). a.a., amino acids.
S. Bae et al. / FEBS Letters 586 (2012) 3057–3063 3061the interaction between p53 and MDM2 was substantially de-
creased following TRIAD1 transfection. We next identiﬁed which
region of TRIAD1 could affect p53-MDM2 interaction. Because a
previous in vitro study demonstrated that RING mutant MDM2
does not affect the MDM2-p53 interaction [13], we performed a
series of immunoprecipitation experiments using RING mutant
MDM2 constructs (Fig. 4C). In particular, the N-terminus of TRIAD1
(1–246) was found to be critical for the dissociation of p53 from
MDM2 (Fig. 4C). Interestingly, the interaction between p53 and
MDM2 is orchestrated by the interaction of TRIAD1 with p53;
full-length TRIAD1 and the N-terminus of TRIAD1 (1–246) were
capable of binding to p53 and inhibiting its interaction with
MDM2, whereas the C-terminus of TRIAD1 (247–493) was unable
to do either (Fig. 4C). These results indicate that TRIAD1 hinders
MDM2-mediated p53 ubiquitination by inhibiting the interaction
between p53 and MDM2.3.5. TRIAD1 interacts with the C-terminus of p53
Because TRIAD1 interacts with p53 and induces its dissociation
fromMDM2 (Fig. 4), we performed experiments to identify the p53
domain that is critical for TRIAD1 interaction. Several fragmented
p53 constructs were prepared as indicated (Fig. 5A). Interestingly,
in vitro binding assays using these fragmented constructs with a
GST-TRIAD1 fusion protein revealed that the C-terminus of p53 is
critical for the interaction between p53 and TRIAD1 (Fig. 5B).
3.6. TRIAD1 negatively regulates MDM2 function by inhibiting p53-
mediated cell growth suppression
Because TRIAD1 induces the dissociation of p53 from MDM2,
we evaluated whether TRIAD1 restores p53 activation in presence
of MDM2. We cotransfected p53/ mdm2/MEF cells with p53 or
Fig. 5. The C-terminus of p53 interacts with TRIAD1. (A) Schematic representation of the generated p53 fragment constructs. The p53 fragment constructs were cloned into
pcDNA3.1 vectors. (B) In vitro pull-down assay showing the interactions between in vitro-translated, 35S-labeled p53 fragments, and GST or GST-TRIAD1 after a 1-h
incubation at room temperature. Bound proteins were detected by autoradiography. a.a., amino acids.
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sence of TRIAD1. We found that TRIAD1 reduces cell viability
through p53 activation in the presence of ectopic MDM2 expres-
sion (Fig. 6A). The cytotoxic function of TRIAD1 was found to be
defective in p53/ mdm2/ MEF cells (Fig. S2). Moreover, the N-
terminal fragment of TRIAD1, which is capable of interacting with
p53, induced p53-mediated cellular growth inhibition, whereas theFig. 6. TRIAD1 restores p53-mediated cell growth inhibition in the presence of MDM2. (
after transfection, cell viability was determined by three independent MTS assays. (B) p5
GFP-TRIAD1, GFP-TRIAD1 (a.a. 1–246), GFP-TRIAD1 (a.a. 247–493), or control GFP. Coloni
acids.C-terminal fragment did not. These results indicate that TRIAD1 in-
duces p53-mediated cellular growth inhibition by binding to p53,
thereby inhibiting its interaction with MDM2. We also evaluated
whether TRIAD1 restores p53-mediated clonogenic growth inhibi-
tion in the presence of MDM2. As shown in Fig. 6B, p53 transfec-
tion inhibited clonogenic growth, which was restored by TRIAD1
transfection in the presence of MDM2.A) p53/mdm2/ MEF cells were transfected with the indicated plasmids. At 72 h
3/mdm2/ MEF cells were cotransfected with plasmids for HA-p53, FLAG-MDM2,
es were counted 2 week after seeding using a standard clonogenic assay. a.a., amino
S. Bae et al. / FEBS Letters 586 (2012) 3057–3063 30634. Discussion
We previously demonstrated that TRIAD1 expression induces
p53 activation and subsequent apoptosis [8]. The present work
examines the role of TRIAD1 in p53 stabilization and activation.
We found that p53 protein levels were lower and p53 activity
was decreased in TRIAD1-knockdown cells compared to control
U2OS cells. Cotransfection of TRIAD1 and p53 failed to induce
p53 activation in p53/ mdm2/ MEF cells, however, transfection
of TRIAD1 and MDM2 inhibited MDM2-mediated p53 degradation,
indicating that TRIAD1-mediated p53 activation is related to the
MDM2-antagonizing function of TRIAD1. Indeed, MDM2 suppres-
sion of p53-mediated cell growth inhibition was blocked by
TRIAD1 expression. Furthermore, although TRIAD1 expression did
not inhibit p53/ mdm2/ MEF cell viability, it did affect cell via-
bility in MDM2-transfected cells.
Several p53-interacting proteins that function as MDM2 antag-
onists have been reported. For example, ARF, L5, L11, and L23 can
interact with MDM2 [5] and inhibit MDM2-mediating p53 ubiqui-
tination/degradation. However, TRIAD1 interacts with and stabi-
lizes p53 but not MDM2. Although the transactivation domain
located in the N-terminus of p53 is important for MDM2 interac-
tion [14], a recent report suggests that the C-terminus of p53,
which contains multiple lysine residues, is also important for this
interaction [15]. In the present study, we demonstrated that
TRIAD1 binds to the C-terminus of p53 and inhibits MDM2 interac-
tion, as well as MDM2-mediated ubiquitination. Thus, the C-termi-
nus of p53 is important for regulation of its activity, not only via
post-translational modiﬁcations but also through its interaction
with TRIAD1.
Recently, TRIAD1 transcription was found to be directly pro-
moted by the transcription factor HoxA10 and induces anti-prolif-
erative effects in acute myeloid leukemia (AML) [16]. In addition,
HoxA10 reduces breast cancer cell invasiveness by upregulating
p53 protein; however, the mechanism is unknown [17]. There-
fore, our results extend the possibility that HoxA10-mediated
p53 upregulation is related to HoxA10-mediated TRIAD1
expression.
Although ectopic TRIAD1 expression induces apoptosis in sev-
eral cell lines [18], it is possible that TRIAD1 also mediates differ-
entiation for the following reasons: (1) TRIAD1 expression levels
are greatly increased following treatment with all-trans retinoic
acid (ATRA), which affects cellular differentiation [19,20]; (2)
growth factor independent-1 (Gﬁ-1) transcription repressor, which
is known to be stabilized by TRIAD1, is critical for B cell and mye-
loid cell development and neutrophil differentiation [21,22]; and
(3) p53 activation regulates differentiation in several cell lines
[23–25]. Moreover, modulation of the p53-MDM2 loop by nutlin
decreases preosteoclast differentiation [26]. Thus, the physiologi-
cal effects of TRIAD1 on p53 activation warrant further
investigation.
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